"Cheap stock" is the SEC's shorthand for equity awards granted in the runway to an IPO at a fair value that, in hindsight, looks too low relative to the offering price. The exposure is real: understated grant-date fair value understates stock-compensation expense under ASC 718, and the SEC routinely asks registrants to bridge every grant in the trailing 12–18 months up to the IPO price. The way to stay out of that conversation is not to guess the IPO price early — it's to obtain contemporaneous, independent valuations at each grant date, choose an allocation method (OPM, PWERM, or a hybrid) that matches where the company actually is, reconcile each value to real signals like secondary sales and new financing rounds, and disclose the methodology and the ramp clearly in MD&A before the staff asks.
Every company heading to an IPO grants equity on the way there — options and RSUs to employees hired in the final two years before the S-1, refresh grants to retain the team through the offering, and founder or executive awards tied to the transaction. Each of those grants carries a fair value, and each fair value drives a stock-based compensation charge under ASC 718 and a tax-side valuation under IRC Section 409A. When the eventual IPO price sits well above the fair values used for those late grants, the SEC wants to understand why — and "cheap stock" is the label for the gap.
The stakes are concrete. A common-stock value that is too low understates compensation expense across the vesting period, distorts the pre-IPO income statement, and — if the staff disagrees with the company's support — can force a restatement of the very financials inside the registration statement. It can also expose employees to 409A penalties on options priced below fair market value. None of this is exotic, and none of it is unavoidable. It is a documentation and process problem, and the companies that handle it well start 18 to 24 months before they expect to file.
Why "cheap stock" exists as a concept
Private-company common stock has no observable market price, so its fair value is an estimate. Under ASC 718, the measurement objective for an award is grant-date fair value, and for options that means running an option-pricing model on an estimated value of the underlying common share. Under IRC 409A, the same underlying value has to be set at or above fair market value to keep the option out of deferred-compensation penalty territory. Both regimes lean on the same input: what is a share of common worth today?
The tension is timing. In the ordinary course, a private company's board sets that value using a 409A appraisal refreshed every 12 months or upon a material event. But as an IPO approaches, value can move quickly — a strong quarter, a new lead investor, improving market comparables — and the offering price ultimately reflects public-market demand that did not exist at the earlier grant dates. When the staff sees a $4.00 grant in March and a $15.00 IPO in November, the natural question is whether the March value was genuinely supportable or whether the company under-valued its stock to hand employees a discounted award. Answering that question convincingly is the whole game.
The governing framework: the AICPA practice aid
The authoritative playbook here is the AICPA Accounting and Valuation Guide, Valuation of Privately-Held-Company Equity Securities Issued as Compensation — universally called the "cheap stock guide." It is not GAAP, but auditors and SEC staff treat it as best practice, and a valuation that departs from it needs a reason. Three of its themes drive almost every cheap-stock discussion.
Contemporaneous beats retrospective. A valuation prepared at or near the grant date, by a qualified independent specialist, is far stronger than one prepared after the fact to justify a value already used. The guide is explicit that retrospective valuations are disfavored, and the SEC reads them as a red flag. Companies that grant on a predictable cadence and refresh the 409A on that same cadence rarely have to reach for a retrospective analysis.
The valuation must reflect an IPO scenario once one is reasonably possible. Early in a company's life, a going-concern, stay-private outcome dominates the analysis. As an offering becomes a realistic path, the probability and value of the IPO scenario have to be weighted into the common-stock value — which naturally lifts it. A valuation that keeps assuming "no near-term liquidity" while the company is interviewing bankers is the classic cheap-stock setup.
Independence and qualifications matter. Boards can determine fair value, but a valuation performed or reviewed by a qualified, independent third party earns the 409A safe harbor and carries far more weight with auditors. In the pre-IPO window, an independent specialist is effectively mandatory.
Choosing an allocation method: OPM, PWERM, or hybrid
Once the total equity value is estimated, it has to be allocated across the company's preferred and common classes — and the method chosen is one of the first things a reviewer looks at. Three approaches dominate.
The Option Pricing Method (OPM) treats each equity class as a call option on total enterprise value, using a Black-Scholes framework to allocate value across the preferred stack's liquidation preferences and conversion rights. It is well suited to earlier stages where the range of outcomes is wide and continuous and no single exit path is clearly more likely than another. Its weakness near an IPO is that it tends to under-weight the specific, high-value liquidity event that management is actively pursuing.
The Probability-Weighted Expected Return Method (PWERM) models discrete future outcomes — IPO, sale, stay-private, dissolution — assigns a probability and a common-share value to each, and weights them. It shines as an IPO comes into focus because it lets the analysis capture the actual price and timing management expects in an offering, net of a discount for the fact that it hasn't happened yet. Its weakness is that it is only as good as its scenario inputs, and it invites scrutiny of every assumption.
The hybrid method blends the two — typically PWERM for the near-term IPO and sale scenarios and OPM for the residual stay-private outcome. For most companies in the 12-to-24-month pre-IPO window, the hybrid is the natural home. It acknowledges the offering is a live possibility without pretending it is a certainty, and it produces the rising value profile the SEC expects to see as the filing approaches.
A related mechanic worth naming: the backsolve. When a company closes a financing round at a known price, the OPM can be run in reverse to solve for the total equity value implied by that arm's-length transaction, and the common value falls out of that solve. A recent, meaningful round priced by a new outside investor is among the strongest possible anchors for a valuation — and one the staff will expect the company to have used.
The discount for lack of marketability
Common stock in a private company can't be sold freely, so its value is reduced by a discount for lack of marketability (DLOM). The size of that discount is one of the most contested single inputs in a cheap-stock review. Early on, DLOMs in the 25–40% range are common; as an IPO nears and a liquid market becomes weeks away rather than years, the defensible discount compresses toward the low teens or single digits.
The mistake to avoid is a DLOM that stays flat while everything else about the company screams imminent liquidity. If the probability-weighted time to a liquidity event is six months, a 35% discount is very hard to defend, and it is exactly the kind of stale input that produces a cheap-stock charge. Whatever method is used to size the discount — protective-put models, restricted-stock studies, or option-based approaches — the analysis should show the discount shrinking as the offering approaches, in step with the shortening horizon.
Reconciling to real-world signals
A valuation that lives only inside a model is fragile. The strongest defenses tie each grant-date value to independent, external evidence. Secondary transactions — employees or early investors selling shares in tender offers or private sales — are treated by the SEC as some of the best available evidence of common-stock value, and a 409A value materially below recent secondary prices will draw a comment. New primary financing rounds priced by outside investors set a ceiling and a reference point through the backsolve. Changes in comparable public-company multiples explain why value moved between valuation dates. When each step up in the common value maps to an identifiable event — a round, a secondary, a step-change in results, a shift in market comps — the ramp tells a coherent story rather than looking like a series of convenient guesses.
What the SEC actually asks for
Cheap-stock comments follow a familiar pattern. The staff asks the registrant to provide a table of every equity grant for roughly the 12 to 18 months preceding the filing, showing grant date, number of shares, exercise price, the fair value of the underlying common used for ASC 718, and the intrinsic value per share by reference to the estimated IPO price. They then ask the company to reconcile the difference between the most recent pre-IPO fair value and the midpoint of the expected offering range — explaining, event by event, what changed. If the reconciliation is thin, or if a grant sits far below contemporaneous secondary activity, the follow-up questions get pointed and the timeline gets tight.
Two disclosure obligations flow from this. First, stock-based compensation and the underlying common-stock valuation almost always belong in MD&A as a critical accounting estimate, with a description of the methodology, the significant assumptions, and their sensitivity. Second, once the offering range is set, the company should be prepared to walk the staff through the bridge from its last valuation to that range. Companies that have built this narrative contemporaneously simply hand it over; companies that haven't spend precious pre-effectiveness weeks reconstructing it.
The IPO price is not evidence that your earlier valuations were wrong. It is evidence of what a public market will pay on a specific day — and your job is to show, grant by grant, that each earlier value was reasonable given what was known then.
Getting ahead of it: a pre-IPO cadence
The companies that never have a cheap-stock problem tend to run the same disciplined process. They refresh the 409A every quarter in the final year or two rather than annually, so no grant is ever priced off a stale appraisal. They align grant timing with valuation dates, concentrating awards shortly after each fresh valuation rather than scattering them across a period when value is moving. They switch to a hybrid or PWERM method the moment an IPO becomes a realistic scenario and let the IPO probability and DLOM move accordingly. They keep a running reconciliation file that logs every round, secondary, and material event alongside the corresponding valuation, so the bridge to the eventual offering price is written as events happen. And they bring the auditors into the valuation approach early, because the audit of stock-comp expense inside the S-1 financials is smoother when the methodology was agreed in advance rather than debated at the finish line.
Done this way, cheap stock stops being a filing-season fire drill and becomes a routine quarterly control. The valuations rise as the business does, each step is explainable, and the reconciliation the SEC asks for already exists.
What CFOs and audit committees should confirm each quarter
A short set of questions surfaces most of the exposure. Is the current 409A valuation less than 12 months old — and given where we are, should it be refreshed sooner? Have we granted any equity since the last valuation date, and if so, was the value used still supportable at the grant date? Has any secondary transaction or new financing round occurred that a reviewer would treat as evidence of common-stock value, and does our latest valuation reconcile to it? Does our allocation method still fit our stage, or has an IPO become likely enough to move to a hybrid or PWERM approach? Each has a clean answer in most quarters; the discipline is asking before the underwriters and the staff ask first.
If you're heading toward an IPO in the next year or two and want a second set of eyes on your 409A cadence, grant timing, and stock-compensation disclosures — and help coordinating with your valuation specialist so the whole package holds up to a cheap-stock review — we'd be glad to help.
This article is for general informational purposes and should not be relied on as accounting, tax, or legal advice for any specific transaction. Valuation and 409A matters are highly facts-and-circumstances dependent; please consult with your advisors.